At a glance
ClinicalIndex Comparison RecordN/AActive· 66 target
Drug / intervention
placeboother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05351333N/AActiveUpdate OverdueUpdated 8mo ago · Completion was 11mo agoEnrollment Stalled
Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation
In Brief
A clinical study evaluating placebo for Spinal Cord Injuries and 2 related conditions. Active but no longer recruiting, targeting 66 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The use of the conditioning open-label placebo (COLP) paradigm will be studied as a dose extension method to lower opioid dosage in patients with spinal cord injury, polytrauma, and burn injury. The goal is to provide the same level of pain relief with a reduced opioid intake to diminish side effects as well as the risk of addiction associated with opioid treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries, Polytrauma, Burns
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
N/AActive
2023202420252026
First PostedApr 2022
Enrollment StartAug 2022
Primary CompletionJul 2025
TodayJul 2026
Study CompletionJul 2026
First PostedApr 28, 2022
Enrollment StartAug 3, 2022
Primary CompletionJul 31, 2025
Study CompletionJul 31, 2026
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.2 years ago
Interventions
placeboother
Sugar pill, with an essential-oil smell and of blue color used for conditioning.